Det er ikke vist, at APTIVUS er overlegen til disse boostede komporator protease- inhibitor hos patienter, der har stammer, som er modtagelige over for disse proteasehæmmere.
It has not been shown that APTIVUS is superior to these boosted comparator protease inhibitors in patients harbouring strains susceptible to these protease inhibitors.